FINANCIAL TEAR SHEET

CORPORATE PROFILE

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and ß-thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

PRIMARY IR CONTACT

Chris Brinzey
Westwicke Partners
Phone: 339-970-2843
E-mail:
chris.brinzey@westwicke.com

STOCK PERFORMANCE

CRSP (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	**$58.35**
Change (%)	▼0.04 (0.07%)
Volume	687,323
52 Week Low	$16.15
Market Cap	$2,723,825,555
Rolling EPS	-1.63
PE Ratio	0
Shares Outstanding	46,680,815

Data as of 07/20/18 4:00 p.m. ET



RECENT HEADLINES & EVENTS

Jun-19-2018 - 9:05 a.m.
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

Jun-05-2018 - 8:00 a.m.
CRISPR Therapeutics to Participate in Three June Conferences

May-30-2018 - 4:30 p.m.
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
07/05/18	4
06/19/18	4
06/18/18	4
06/15/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources